```
=> d his nofil

     (FILE 'HOME' ENTERED AT 09:53:21 ON 25 OCT 2006)

     FILE 'REGISTRY' ENTERED AT 09:53:31 ON 25 OCT 2006
L*** DEL         STR
L1               STRUCTURE UPLOADED
L2            50 SEA SSS SAM L1

     FILE 'STNGUIDE' ENTERED AT 10:08:45 ON 25 OCT 2006

     FILE 'REGISTRY' ENTERED AT 10:12:41 ON 25 OCT 2006
L3               STRUCTURE UPLOADED
L4             0 SEA SSS SAM L3
L5               STRUCTURE UPLOADED
L6             0 SEA SSS SAM L5
L7               STRUCTURE UPLOADED
L8             1 SEA SSS SAM L7
                 D SCA

     FILE 'HCAPLUS' ENTERED AT 10:17:55 ON 25 OCT 2006
L9             1 SEA ABB=ON  PLU=ON  L8
                 D BIB

     FILE 'REGISTRY' ENTERED AT 10:18:15 ON 25 OCT 2006
                 D QUE L3
                 D QUE L5
L10      2827645 SEA ABB=ON  PLU=ON  NR>1 AND N>0 AND S>0 AND O>3 AND NRS>1
L11            0 SEA SUB=L10 SSS SAM L5
L12           35 SEA SUB=L10 SSS FUL L5
                 D QUE

     FILE 'HCAPLUS' ENTERED AT 10:25:01 ON 25 OCT 2006
L13           14 SEA ABB=ON  PLU=ON  L12
                 D QUE L7

     FILE 'BEILSTEIN' ENTERED AT 10:26:38 ON 25 OCT 2006
L14              STRUCTURE UPLOADED
L15            0 SEA SSS SAM L14
L16            0 SEA SSS FUL L14

=> fil hcap
FILE 'HCAPLUS' ENTERED AT 10:32:03 ON 25 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 25 Oct 2006  VOL 145 ISS 18
FILE LAST UPDATED: 24 Oct 2006  (20061024/ED)
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que l13
L5 STR



G1 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.
L10 2827645 SEA FILE=REGISTRY ABB=ON PLU=ON NR>1 AND N>0 AND S>0 AND O>3 AND NRS>1
L12 35 SEA FILE=REGISTRY SUB=L10 SSS FUL L5
L13 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L12

=> d l13 ibib abs hitstr 1-14

L13 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:693723 HCAPLUS Full-text
DOCUMENT NUMBER: 143:172647
TITLE: Preparation of sulfonamides and their use as acyl-CoA:diacylglycerol acyltransferase (DGAT) inhibitors
INVENTOR(S): Yoshida, Masao; Hayakawa, Ichio; Kanno, Yuichi; Furuhama, Takafumi; Tanimoto, Tatsuo; Karasawa, Hiroshi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 186 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005206492	A2	20050804	JP 2004-13099	20040121
PRIORITY APPLN. INFO.:			JP 2004-13099	20040121
OTHER SOURCE(S):	MARPAT 143:172647			

AB Title inhibitors, useful for prophylactic and therapeutic treatment of obesity, hyperlipidemia, diabetes, arteriosclerosis, etc., contain A1R1CHR2NA2SO2A3 [I: A1 = (un)substituted C1-8 alkyl, (un)substituted phenyl-(C1-6 alkyl), (un)substituted phenoxy-(C1-6 alkyl), (un)substituted C3-8 cycloalkyl, (un)substituted naphthyl, etc.; A2 = (un)substituted di(C1-6 alkyl)amino-(C1-6 alkyl), similar groups as in A1; A3 = (un)substituted naphthylmethyl, similar groups as in A1; R1 = NHCO (substituted with C1-6 alkyl), CO; R2 = H, C1-6 alkyl] or their pharmacol. acceptable salts as active


O
CH2
C
OEt
O
S
N
O
Me
Ph

STIC STN Search
4/10/2007

```
=> d his nofil

     (FILE 'HOME' ENTERED AT 09:53:21 ON 25 OCT 2006)

     FILE 'REGISTRY' ENTERED AT 09:53:31 ON 25 OCT 2006
L*** DEL         STR
L1               STRUCTURE UPLOADED
L2            50 SEA SSS SAM L1

     FILE 'STNGUIDE' ENTERED AT 10:08:45 ON 25 OCT 2006

     FILE 'REGISTRY' ENTERED AT 10:12:41 ON 25 OCT 2006
L3               STRUCTURE UPLOADED
L4             0 SEA SSS SAM L3
L5               STRUCTURE UPLOADED
L6             0 SEA SSS SAM L5
L7               STRUCTURE UPLOADED
L8             1 SEA SSS SAM L7
                 D SCA

     FILE 'HCAPLUS' ENTERED AT 10:17:55 ON 25 OCT 2006
L9             1 SEA ABB=ON  PLU=ON  L8
                 D BIB

     FILE 'REGISTRY' ENTERED AT 10:18:15 ON 25 OCT 2006
                 D QUE L3
                 D QUE L5
L10      2827645 SEA ABB=ON  PLU=ON  NR>1 AND N>0 AND S>0 AND O>3 AND NRS>1
L11            0 SEA SUB=L10 SSS SAM L5
L12           35 SEA SUB=L10 SSS FUL L5
                 D QUE

     FILE 'HCAPLUS' ENTERED AT 10:25:01 ON 25 OCT 2006
L13           14 SEA ABB=ON  PLU=ON  L12
                 D QUE L7

     FILE 'BEILSTEIN' ENTERED AT 10:26:38 ON 25 OCT 2006
L14              STRUCTURE UPLOADED
L15            0 SEA SSS SAM L14
L16            0 SEA SSS FUL L14

=> fil hcap
FILE 'HCAPLUS' ENTERED AT 10:32:03 ON 25 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Oct 2006  VOL 145 ISS 18
FILE LAST UPDATED: 24 Oct 2006  (20061024/ED)
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que l13
L5 STR



G1 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.
L10 2827645 SEA FILE=REGISTRY ABB=ON PLU=ON NR>1 AND N>0 AND S>0 AND O>3 AND NRS>1
L12 35 SEA FILE=REGISTRY SUB=L10 SSS FUL L5
L13 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L12

=> d l13 ibib abs hitstr 1-14

L13 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:693723 HCAPLUS Full-text
DOCUMENT NUMBER: 143:172647
TITLE: Preparation of sulfonamides and their use as acyl-CoA:diacylglycerol acyltransferase (DGAT) inhibitors
INVENTOR(S): Yoshida, Masao; Hayakawa, Ichio; Kanno, Yuichi; Furuhama, Takafumi; Tanimoto, Tatsuo; Karasawa, Hiroshi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 186 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005206492	A2	20050804	JP 2004-13099	20040121
PRIORITY APPLN. INFO.:			JP 2004-13099	20040121
OTHER SOURCE(S):		MARPAT 143:172647		

AB Title inhibitors, useful for prophylactic and therapeutic treatment of obesity, hyperlipidemia, diabetes, arteriosclerosis, etc., contain A1R1CHR2NA2SO2A3 [I: A1 = (un)substituted C1-8 alkyl, (un)substituted phenyl-(C1-6 alkyl), (un)substituted phenoxy-(C1-6 alkyl), (un)substituted C3-8 cycloalkyl, (un)substituted naphthyl, etc.; A2 = (un)substituted di(C1-6 alkyl)amino-(C1-6 alkyl), similar groups as in A1; A3 = (un)substituted naphthylmethyl, similar groups as in A1; R1 = NHCO (substituted with C1-6 alkyl), CO; R2 = H, C1-6 alkyl] or their pharmacol. acceptable salts as active

ingredients. Thus, p-phenetidine was bromoacetylated, aminated with 3-trifluoromethylaniline, and amidated with PhSO2Cl in microreactor containing 2-(3,5-dimethoxy-4- formylphenoxy)ethoxymethylated polystyrene using the encoding method to give I (A1 = 4-EtOPh, A2 = 3-CF3Ph, A3 = Ph, R1 = NHCO, R2 = H), which at 1 μg/mL inhibited ≥40% murine DGAT1.

IT ***861246-62-0P 861246-63-1P***

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of sulfonamides as acyl-CoA:diacylglycerol acyltransferase inhibitors for treatment of diseases)

RN 861246-62-0 HCAPLUS

CN Acetamide, 2-[[1,1'-biphenyl]-2-yl(1-naphthalenylsulfonyl)amino]-N-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 861246-63-1 HCAPLUS

CN Acetamide, 2-[[1,1'-biphenyl]-3-yl(1-naphthalenylsulfonyl)amino]-N-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:378875 HCAPLUS Full-text
DOCUMENT NUMBER: 143:19267
TITLE: Structure-based design of protein tyrosine phosphatase-1B inhibitors
AUTHOR(S): Black, Emma; Breed, Jason; Breeze, Alexander L.; Embrey, Kevin; Garcia, Robert; Gero, Thomas W.; Godfrey, Linda; Kenny, Peter W.; Morley, Andrew D.; Minshull, Claire A.; Pannifer, Andrew D.; Read, Jon; Rees, Amanda; Russell, Daniel J.; Toader, Dorin; Tucker, Julie
CORPORATE SOURCE: AstraZeneca, Cheshire, SK10 4TG, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(10), 2503-2507
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:19267

AB Using structure-based design, a new class of inhibitors of protein tyrosine phosphatase-1B (PTP1B) has been identified, which incorporate the 1,2,5-thiadiazolidin-3-one-1,1-dioxide template.

IT ***852835-51-9P***
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(structure-based design of protein tyrosine phosphatase-1B inhibitors)

RN 852835-51-9 HCAPLUS
CN Glycine, N-(aminosulfonyl)-N-(4-methoxy[1,1'-biphenyl]-3-yl)-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1154657 HCAPLUS Full-text
DOCUMENT NUMBER: 142:56659
TITLE: Preparation of N-arylglycine derivatives and related compounds as inhibitors of matrix metalloproteinase
INVENTOR(S): Holmes, Ian; Watson, Stephen Paul
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113279	A1	20041229	WO 2004-EP6553	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1636174	A1	20060322	EP 2004-740011	20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
US 2006142385	A1	20060629	US 2005-561055	20051216
PRIORITY APPLN. INFO.:			GB 2003-14488 A	20030620
			WO 2004-EP6553 W	20040616

OTHER SOURCE(S): MARPAT 142:56659

AB The invention relates to compds. R1-Z-Q-NR2CH2-X [R1 is optionally substituted alkyl, alkylaryl, aryl or heteroaryl; Z is a bond, CH2, O, S, SO, SO2, NR4, OCR4R5, CR4R5O, or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q is an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X is COR3 or N(OR8)COR9; R2 is SO2R10 or SO2NR10R11; R3 is OR6, NR6R7 or NR6OH; R4, R5 are independently H, alkyl or alkylaryl; R6, R7 are independently H, alkyl or heteroarylalkyl or NR6R7 is a 5- or 6- membered ring which may have one or more addnl. heteroatoms selected from O, S and N; R8-R11 are independently H or alkyl] and physiol. functional derivs., with the exception of N-(ethoxycarbonyl)-N-[4-(1H-tetrazol-1-yl)phenyl]glycine, for use as inhibitors of matrix metalloproteinase enzymes (MMPs). Thus, p-NCC6H4C6H4-p-N(SO2Me)CH2CO2H was prepared by alkylation of 4-bromoaniline with tert-Bu bromoacetate, followed by methylsulfonylation, ester cleavage (silica gel in toluene at reflux), and reaction with cyanophenylboronic acid.

IT ***808748-23-4P 808748-25-6P 808748-27-8P 808748-28-9P 808748-30-3P 808748-32-5P 808748-34-7P 808748-36-9P 808748-38-1P***

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-arylglycine derivs. and related compds. as inhibitors of matrix metalloproteinase)

RN 808748-23-4 HCAPLUS

CN Glycine, N-(4'-cyano[1,1'-biphenyl]-4-yl)-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 808748-25-6 HCAPLUS
CN Glycine, N-(methylsulfonyl)-N-[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-(9CI) (CA INDEX NAME)



RN 808748-27-8 HCAPLUS
CN Glycine, N-(4'-acetyl[1,1'-biphenyl]-4-yl)-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 808748-28-9 HCAPLUS
CN Glycine, N-(4'-methoxy[1,1'-biphenyl]-4-yl)-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 808748-30-3 HCAPLUS
CN Glycine, N-(4'-methyl[1,1'-biphenyl]-4-yl)-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 808748-32-5 HCAPLUS
CN Glycine, N-(3'-cyano[1,1'-biphenyl]-4-yl)-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 808748-34-7 HCAPLUS
CN Glycine, N-(3'-acetyl[1,1'-biphenyl]-4-yl)-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 808748-36-9 HCAPLUS
CN Glycine, N-(4'-ethoxy[1,1'-biphenyl]-4-yl)-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 808748-38-1 HCAPLUS
CN Glycine, N-[1,1'-biphenyl]-4-yl-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1127325 HCAPLUS Full-text
DOCUMENT NUMBER: 142:74359
TITLE: Synthesis of N-hydroxy-7-(arylamino)heptanamide derivatives useful for treating hyper-proliferative disorders
INVENTOR(S): Kluender, Harold C. E.; Hong, Zhenqiu; Ladouceur, Gaetan H.; Liu, Xiao-Gao; Khire, Uday; Wang, Lei
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110989	A1	20041223	WO 2004-US15465	20040513

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-470713P P 20030514
OTHER SOURCE(S): MARPAT 142:74359
GI



I

AB This invention relates to the preparation of N-hydroxy-7-(arylamino)heptanamide derivs. R-Ar-N(R1)(CH2)6CONHOH [Ar = Ph, 3-quinolyl, 5-indolyl, 5-indazolyl; R = H, thienyl, naphthyl, benzofuranyl, benzothiophenyl, etc.; R1 = H, C(O)W, C(O)NHX, S(O)2Y, W = naphthyl, thienyl, furyl, benzothienyl, C1-C8 alkyl, C3-C6-cycloalkyl, etc.; X = naphthyl, furyl, C1-C8-alkyl, C3-C6-cycloalkyl, etc.; Y = thienyl, benzothienyl, C1-C8-alkyl, C3-C6-cycloalkyl, etc.] including salts, carbonates and O-acylated derivs. thereof, pharmaceutical compns. containing such compds., and the use of those compds. or compns. for treating hyper-proliferative disorders, specifically cancer.

For example, 5-aminoindole reacted with Et 7-bromoheptanoate to give (indolylamino)heptanoate I (R1= H, R2 = OEt). I (R1 = H, R2 = OEt) was condensed with 2-thiophenesulfonyl chloride to give I (R1 = thienylsulfonyl) which was converted to the Et ester and then reacted with hydroxylamine hydrochloride to give the desired compound I (R2 = NHOH). These compds. were examined for their antiproliferative activity against colon carcinoma cells (HCT 116) and lung carcinoma cells (A549).

IT ***811797-03-2P 811797-07-6P***

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-hydroxy-7-(arylamino)heptanamide derivs. and antitumor activity)

RN 811797-03-2 HCAPLUS

CN Heptanamide, N-hydroxy-7-[(2-thienylsulfonyl)(3',4',5'-trimethoxy[1,1'-biphenyl]-4-yl)amino]- (9CI) (CA INDEX NAME)



RN 811797-07-6 HCAPLUS

CN Heptanamide, N-hydroxy-7-[(4'-methyl[1,1'-biphenyl]-4-yl)(2-thienylsulfonyl)amino]- (9CI) (CA INDEX NAME)



IT ***811796-99-3P 811797-01-0P 811797-05-4P 811797-06-5P 811797-08-7P 811797-09-8P 811797-10-1P 811797-11-2P 811797-12-3P***

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-hydroxy-7-(arylamino)heptanamide derivs. and antitumor activity)

RN 811796-99-3 HCAPLUS

CN Heptanamide, 7-[(4'-ethoxy[1,1'-biphenyl]-4-yl)(2-thienylsulfonyl)amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 811797-01-0 HCAPLUS
CN Heptanamide, 7-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl](2-thienylsulfonyl)amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 811797-05-4 HCAPLUS
CN Heptanamide, 7-[(4'-ethyl[1,1'-biphenyl]-4-yl)(2-thienylsulfonyl)amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 811797-06-5 HCAPLUS
CN Heptanamide, 7-[[1,1'-biphenyl]-4-yl(2-thienylsulfonyl)amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 811797-08-7 HCAPLUS
CN Heptanamide, N-hydroxy-7-[[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl](2-thienylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 811797-09-8 HCAPLUS
CN Heptanamide, N-hydroxy-7-[(2-thienylsulfonyl)[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 811797-10-1 HCAPLUS
CN Heptanamide, N-hydroxy-7-[(3'-methyl[1,1'-biphenyl]-4-yl)(2-thienylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 811797-11-2 HCAPLUS
CN Heptanamide, 7-[(3',5'-dimethoxy[1,1'-biphenyl]-4-yl)(2-thienylsulfonyl)amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 811797-12-3 HCAPLUS

CN Heptanamide, N-hydroxy-7-[(2-thienylsulfonyl)[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:996149 HCAPLUS Full-text
DOCUMENT NUMBER: 141:424430
TITLE: Preparation of phenyl substituted carboxylates, including amino acid derivatives, as inhibitors of protein tyrosine phosphatases for treatment of diabetes, cancer, and related conditions
INVENTOR(S): Whitehouse, Darren; Hu, Shaojing; Fang, Haiquan; Van Zandt, Michael
PATENT ASSIGNEE(S): The Institute of Pharmaceutical Discovery, Llc, USA
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099170	A2	20041118	WO 2004-US13701	20040430
WO 2004099170	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004236248	A1	20041118	AU 2004-236248	20040430
CA 2524235	AA	20041118	CA 2004-2524235	20040430
US 2005004369	A1	20050106	US 2004-835924	20040430
EP 1620422	A2	20060201	EP 2004-751193	20040430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009916	A	20060425	BR 2004-9916	20040430
CN 1812978	A	20060802	CN 2004-80018417	20040430
NO 2005005129	A	20060123	NO 2005-5129	20051102
PRIORITY APPLN. INFO.:			US 2003-466868P P	20030430

WO 2004-US13701 W 20040430

OTHER SOURCE(S): MARPAT 141:424430

GI



I



II

AB The invention relates to compds. I [wherein R1 = H, phenyl/alkyl, alkenyl; L2 = a bond, CONH and derivs., NHCO and derivs., etc.; L3 = absent, a bond, alkylene, alkenylene, phenylene, etc.; L5 = a bond, (un)substituted -O-alkylene, alkylene-O, alkylene-S-alkylene, etc.; R20, R21, R22, R23 = independently H, halo, alkyl, OH, alkoxy, NO2, NH2, CN, (un)substituted arylalkoxy, arylalkyl, etc.; A = (un)substituted hetero/aryl, heterocycloalkyl; Q = H, (un)substituted hetero/aryl, heterocycloalkyl, etc.; Z = absent, H, (un)substituted aryl, etc.] and their pharmaceutically acceptable salts which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia (no data). Compds. of the invention include inhibitors of protein tyrosine phosphatases, in particular protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases, and the like (no data). Also disclosed are pharmaceutical compns. comprising compds. of the invention and methods of treating the aforementioned conditions using such compds. For example, II was prepared in 3 steps by reacting 3thiopropanoic acid Me ester with 4-bromobenzyl bromide, coupling with [4'-(Dibenzofuran-4-yl)phenyl]boronic acid, and demethylation. Preferred I exhibited IC50 ≤ 300 nM in an in vitro inhibitory activity test against recombinant human PTP1B with phosphotyrosyl dodecapeptide TRDI(P)YETD(P)Y(P)YRK.

IT ***796739-53-2P***, N-[4'-(1H-Indol-1-yl)biphenyl-4-yl]-N-(phenylsulfonyl)glycine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PTP-1B inhibitor; preparation of Ph substituted carboxylates, including amino acid derivs., as PTP-1B inhibitors for treatment of diabetes, cancer, and related conditions)

RN 796739-53-2 HCAPLUS

CN Glycine, N-[4'-(1H-indol-1-yl)[1,1'-biphenyl]-4-yl]-N-(phenylsulfonyl)-(9CI) (CA INDEX NAME)



L13 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:121146 HCAPLUS Full-text
DOCUMENT NUMBER: 140:321552
TITLE: Palladium-Catalyzed Asymmetric Allylic Substitution of 2-Arylcyclohexenol Derivatives: Asymmetric Total Syntheses of (+)-Crinamine, (-)-Haemanthidine, and (+)-Pretazettine
AUTHOR(S): Nishimata, Toyoki; Sato, Yoshihiro; Mori, Miwako
CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan
SOURCE: Journal of Organic Chemistry (2004), 69(6), 1837-1843
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:321552
GI



I II III

AB Much interest has been shown in Amaryllidaceae alkaloids as synthetic targets due to their wide range of biol. activities. Over 100 alkaloids have been isolated from members of the Amaryllidaceae family; most of them can be classified into eight skeletally homogeneous groups. We have succeeded in the first asym. total syntheses of the crinane-type alkaloids (+)-crinamine, (-)-haemanthidine, and (+)-pretazettine. The starting cyclohexenylamine I (R = SO24-MePh) was obtained from an allyl phosphonate by palladium-catalyzed asym. amination in 82% yield and with 74% ee. The product was recrystd. from MeOH. Interestingly, (-)-I (R = SO24-MePh) with 99% ee was obtained from the mother liquor (74% recovery). An intramol. carbonyl-ene reaction proceeds in a highly stereoselective manner to give hexahydroindole derivative II (R = SO24-MePh) as the sole product. In the Lewis-acid-catalyzed carbonyl-ene reaction, an interesting rearrangement product, III (R = SO24-MePh), was isolated in high yield. From II (R = SO24-MePh), (+)-crinamine was synthesized. Thus, the asym. total synthesis of (+)-crinamine was achieved in 10 steps, and the

overall yield is 19%. The total synthesis of (-)-haemanthidine was also achieved from II (R = SO24-MePh) by a short sequence of steps.

IT ***215609-87-3P***

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-arylcyclohexenol derivs. from cyclohexenes via asym. allylic amination, and an intramol. carbonyl-ene reaction and application to the preparation of (+)-crinamine, (-)-haemanthidine, and (+)-pretazettine)

RN 215609-87-3 HCAPLUS

CN Benzenesulfonamide, N-[(1S)-2-(3,4-dimethoxyphenyl)-2-cyclohexen-1-yl]-4-methyl-N-(2-oxoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:102207 HCAPLUS Full-text

DOCUMENT NUMBER: 134:326190

TITLE: Asymmetric allylic substitution reactions of 2-substituted 2-cycloalkenyl carbonates using 9-PBN-coordinated palladium

AUTHOR(S): Hamada, Y.; Sakaguchi, K.-e.; Hatano, K.; Hara, O.

CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Chiba University, Yayoi-cho, Inage-ku, Chiba, 263-8522, Japan

SOURCE: Tetrahedron Letters (2001), 42(7), 1297-1299
CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:326190

AB 2-Substituted 2-cycloalkenyl carbonates are suitable substrates for asym. allylic substitution reaction using 9-phosphabicyclo[3.3.1]nonane- (9-PBN)-coordinated palladium, producing the allylic substituted products with high enantiomeric excess.

IT ***335640-07-8P***

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (crystal structure)

RN 335640-07-8 HCAPLUS

CN Glycine, N-[(4-methylphenyl)sulfonyl]-N-[(1S)-2-phenyl-2-cyclohexen-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:632431 HCAPLUS Full-text
DOCUMENT NUMBER: 129:343615
TITLE: First Asymmetric Total Syntheses of (+)-Crinamine, (-)-Haemanthidine, and (+)-Pretazettine
AUTHOR(S): Nishimata, Toyoki; Mori, Miwako
CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan
SOURCE: Journal of Organic Chemistry (1998), 63(22), 7586-7587
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:343615
GI



I



II

AB Asym. total syntheses of (+)-crinamine, (-)-haemanthidine, and (+)-pretazettine, which employed an enantioselective, Pd catalyzed amination, was described. Protected alcs. I (R = OCO2Me) or I [R = OP(O)(OEt)2] were reacted with TsNHCH2CH(OEt)2 in the presence of Pd2dba3.CHCl3/(S)-BINAPO catalyst to give amine (S)-I [R = β-N(Ts)CH2CH(OEt)2] with good enantioselectivity, i.e. 60-75% ee. The aldehyde group of (S)-I [R = β-N(Ts)CH2CH(OEt)2] was deprotected with FeCl3/SiO2, and the resulting aldehyde was heated in toluene at 230-240° to obtain II which contains the requisite substructure with the appropriate absolute configuration. II was further converted to the target alkaloids by subsequent synthetic steps.

IT ***215609-87-3***
RL: RCT (Reactant); RACT (Reactant or reagent)
(asym. total syntheses of (+)-crinamine, (-)-haemanthidine, and (+)-pretazettine via enantioselective palladium catalyzed amination)

RN 215609-87-3 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-2-(3,4-dimethoxyphenyl)-2-cyclohexen-1-yl]-4-methyl-N-(2-oxoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:487796 HCAPLUS Full-text
DOCUMENT NUMBER: 122:239700
TITLE: Preparation of imidazopyridines and analogs as angiotensin II antagonists
INVENTOR(S): Machii, Daisuke; Fujiwara, Shigeki; Onoda, Yasuo; Takai, Haruki; Sano, Tomoyuki; Ishikawa, Tomoko; Takahara, Shiho; Yamada, Koji
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06145150	A2	19940524	JP 1992-298664	19921109
PRIORITY APPLN. INFO.:			JP 1992-298664	19921109
OTHER SOURCE(S):	MARPAT 122:239700			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R1, R2 = H, halo, alkyl, etc.; X = (CH2)nCO2R3, etc.; n = 0 or 1; R3 = H, alkyl; Y = O, NR6, etc.; R6 = H, alkyl, etc.; R7 = alkyl, cycloalkyl; R8, R9 = H, halo, etc.] are prepared Imidazopyridine II was prepared in a multiple step process starting with 2-amino-4'-methylbenzophenone. In an in vitro test for angiotensin II antagonist activity, II showed IC50 of 0.013 μM.

IT ***162153-98-2P***
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazopyridines and analogs as angiotensin II antagonists)

RN 162153-98-2 HCAPLUS

CN Glycine, N-(4'-methyl[1,1'-biphenyl]-2-yl)-N-(phenylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1980:41569 HCAPLUS Full-text

DOCUMENT NUMBER: 92:41569

TITLE: Pesticidal and herbicidal sulfonanilides

INVENTOR(S): Cliff, Geoffrey Ross; Hunt, Russell George; Percival, Albert

PATENT ASSIGNEE(S): Fisons Ltd., UK

SOURCE: Ger. Offen., 100 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2854932	A1	19790705	DE 1978-2854932	19781220
GB 2012170	A	19790725	GB 1978-48050	19781212
GB 2012170	B2	19820902		
US 4309559	A	19820105	US 1978-969375	19781214
US 4349378	A	19820914	US 1978-969492	19781214
AT 7808984	A	19820215	AT 1978-8984	19781215
AT 368358	B	19821011		
NL 7812255	A	19790626	NL 1978-12255	19781218
AU 7842626	A1	19790628	AU 1978-42626	19781218
AU 526848	B2	19830203		
DK 7805701	A	19790625	DK 1978-5701	19781219
ES 476119	A1	19791116	ES 1978-476119	19781219
IL 56251	A1	19831031	IL 1978-56251	19781219
BE 872919	A1	19790620	BE 1978-192445	19781220
ZA 7807184	A	19800827	ZA 1978-7184	19781221
CA 1098531	A1	19810331	CA 1978-318426	19781221
CA 1098912	A1	19810407	CA 1978-318425	19781221
FR 2412525	A1	19790720	FR 1978-36222	19781222
DD 143199	C	19800813	DD 1978-210120	19781222
PL 120535	B1	19820331	PL 1978-212112	19781223
JP 54106449	A2	19790821	JP 1978-164590	19781225
PRIORITY APPLN. INFO.:			GB 1977-53902 A	19771224
			GB 1978-31015 A	19780725
			GB 1978-3101578 A	19780725
			GB 1978-48050 A	19781212

OTHER SOURCE(S): MARPAT 92:41569

AB Sulfonanilides RR1NSO2R2 (R = optionally substituted Ph; R1 = alkyl, substituted by CN, a carboxyl derivative, or acyl; R2 = optionally substituted alkyl, aryl, aralkyl, cycloalkyl, heterocyclic, amino) were prepared Thus 2,6-Me2C6H3NH2 was treated with PrSO2Cl to give 55% 2,6-Me2C6H3NHSO2Pr, which was treated with BrCHMeCO2Et to give 73% 2,6- Me2C6H3N(SO2Pr)CHMeCO2H. Esterification of acid with HOCHMe2 gave 2,6--Me2C6H3N(SO2Pr)CHMeCO2CHMe2, which at 11.2 kg/ha post-emergence gave 90% control of Sinapis alba. Other sulfonanilides had fungicidal and bactericidal activity.

IT ***71270-99-0P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 71270-99-0 HCAPLUS

CN Alanine, N-(methylsulfonyl)-N-[3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1971:529645 HCAPLUS Full-text

DOCUMENT NUMBER: 75:129645

TITLE: Approach to dibenzazatropone

AUTHOR(S): Rahman, M. A.

CORPORATE SOURCE: Chem. Dep., Gov. Coll., Lahore, Pak.

SOURCE: Journal of Natural Sciences and Mathematics (1970), 10(1), 161-5
CODEN: JNSMAC; ISSN: 0022-2941

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Detosylation of 5,6-dihydro-7H-5-(p-tolylsulfonyl)dibenz[b,d]azepin-7-one and its 6-Me derivative gave, resp., a Michael-type addition title compound dimer as shown by mass spectra [contrary to that reported by W. Patterson and G. R. Proctor (1962)] and the phenanthridine (I) as shown by ir and NMR spectra.

IT ***19711-93-4P 19711-94-5P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 19711-93-4 HCAPLUS

CN Alanine, N-2-biphenylyl-N-(p-tolylsulfonyl)-, ethyl ester (8CI) (CA INDEX NAME)



RN 19711-94-5 HCAPLUS
CN Alanine, N-2-biphenylyl-N-(p-tolylsulfonyl)- (8CI) (CA INDEX NAME)



L13 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1969:524193 HCAPLUS Full-text
DOCUMENT NUMBER: 71:124193
TITLE: Azabenzocycloheptenones. X. Brominated dibenz[bd] azepines
AUTHOR(S): Proctor, George R.; Peaston, W. C.
CORPORATE SOURCE: Univ. Strathclyde, Glasgow, UK
SOURCE: Journal of the Chemical Society [Section] C: Organic (1969), 16, 2151-3
CODEN: JSOOAX; ISSN: 0022-4952
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Bromination of 5,6-dihydro-5-tolylsulfonyldibenz[b,d]azepin-7-one was studied. 2-Bromo-5,6-dihydro-5-(p-tolylsulfonyl)dibenz[b,d]azepin-7-one (I) was synthesized and converted into several derivs.
IT ***24127-28-4P 24127-29-5P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24127-28-4 HCAPLUS
CN Glycine, N-(5-bromo-2-biphenylyl)-N-(p-tolylsulfonyl)-, ethyl ester (8CI) (CA INDEX NAME)



RN 24127-29-5 HCAPLUS



XI

L13 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1962:462653 HCAPLUS Full-text
DOCUMENT NUMBER: 57:62653
ORIGINAL REFERENCE NO.: 57:12434e-f
TITLE: Azabenzocycloheptenones. IV. An azadibenzotropone
AUTHOR(S): Paterson, W.; Proctor, G. R.
CORPORATE SOURCE: Roy. Coll. Sci. Technol., Glasgow, UK
SOURCE: Journal of the Chemical Society (1962) 3468-72
CODEN: JCSOA9; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 57:62653
GI For diagram(s), see printed CA Issue.
AB cf. CA 56, 4729c. The synthesis of azadibenzotropone (I) was described. I was more polar than was expected.
IT ***94870-32-3***, Glycine, N-2-biphenylyl-N-(p-tolylsulfonyl)-
95941-96-1, Glycine, N-2-biphenylyl-N-(p-tolylsulfonyl)-, methyl ester ***96309-63-6***, Glycine, N-2-biphenylyl-N-(p-tolylsulfonyl)-, ethyl ester
(preparation of)
RN 94870-32-3 HCAPLUS
CN Glycine, N-2-biphenylyl-N-(p-tolylsulfonyl)- (7CI) (CA INDEX NAME)



RN 95941-96-1 HCAPLUS
CN Glycine, N-2-biphenylyl-N-(p-tolylsulfonyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 96309-63-6 HCAPLUS
CN Glycine, N-2-biphenylyl-N-(p-tolylsulfonyl)-, ethyl ester (7CI) (CA INDEX NAME)

CN Glycine, N-(5-bromo-2-biphenylyl)-N-(p-tolylsulfonyl)- (8CI) (CA INDEX NAME)



L13 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1968:496433 HCAPLUS Full-text
DOCUMENT NUMBER: 69:96433
TITLE: Azabenzocycloheptenones. VIII. Further observations in the dibenz[b,d]azepin-7-one field
AUTHOR(S): Peaston, W. C.; Proctor, G. R.
CORPORATE SOURCE: Univ. Strathclyde, Glasgow, UK
SOURCE: Journal of the Chemical Society [Section] C: Organic (1968), (19), 2481-4
CODEN: JSOOAX; ISSN: 0022-4952
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 69:96433
GI For diagram(s), see printed CA Issue.
AB A compound formerly believed to be a monomeric dibenzazatropone is shown to be a dimer (I) and to yield a bisazatropone on oxidation The monomeric dibenzazatropone, 6-ethoxy-7-oxodibenz[b,d]azepine, was prepared Syntheses and reactions of further N-p-tolylsulfonyl-6-substituted dibenz[b,d]azepinones with bases were studied.
IT ***19711-93-4P 19711-94-5P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 19711-93-4 HCAPLUS
CN Alanine, N-2-biphenylyl-N-(p-tolylsulfonyl)-, ethyl ester (8CI) (CA INDEX NAME)



RN 19711-94-5 HCAPLUS
CN Alanine, N-2-biphenylyl-N-(p-tolylsulfonyl)- (8CI) (CA INDEX NAME)